15-Nov-2023	Removal from Official List

14-Nov-2023	Change in substantial holding

13-Nov-2023	Suspension from Official List

8-Nov-2023	Change in substantial holding

3-Nov-2023	Notice of Annual General Meeting/Proxy Form

2-Nov-2023	Preliminary update from ongoing Phase 2 Study of Paxalisib

31-Oct-2023	Proposed issue of securities - KZA

31-Oct-2023	Kazia announces short term unsecured Promissory Note

31-Oct-2023	Quarterly Activities/Appendix 4C Cash Flow Report

27-Oct-2023	Kazia SEC Form 20-F

24-Oct-2023	Kazia announces Clinical Data at ESMO 2023 from EVT801 Study

23-Oct-2023	Change in substantial holding

16-Oct-2023	Change of AGM date

13-Oct-2023	Shareholder communication on the ASX de-listing process

11-Oct-2023	Reinstatement to Official Quotation

11-Oct-2023	Kazia announces intention to voluntarily de-list from ASX

10-Oct-2023	Voluntary Suspension

6-Oct-2023	Trading Halt

5-Oct-2023	Presentations at upcoming scientific meetings

29-Sep-2023	Acceptance of late-breaking abstract of PNOC022 data

11-Sep-2023	Change in substantial holding

31-Aug-2023	2023 Corporate Governance Statement

31-Aug-2023	Appendix 4G

31-Aug-2023	Appendix 4E and 2023 Annual Report

11-Aug-2023	Final Director's Interest Notice - Iain Ross

11-Aug-2023	Cleansing Notice - updated

11-Aug-2023	Cleansing Notice

11-Aug-2023	Application for quotation of securities - KZA

11-Aug-2023	Kazia announces change to Board of Directors

1-Aug-2023	Appointment of Dr John Friend as Managing Director

31-Jul-2023	Quarterly Activities/Appendix 4C Cash Flow Report

19-Jul-2023	Notification regarding unquoted securities - KZA

17-Jul-2023	Change in substantial holding

14-Jul-2023	Cleansing Notice

14-Jul-2023	Appendix 2A

14-Jul-2023	Proposed issue of securities - KZA

13-Jul-2023	Notification of cessation of securities - KZA

11-Jul-2023	Change in substantial holding

7-Jul-2023	Paxalisib receives Fast Track Designation from US FDA

26-Jun-2023	Kazia Corporate Update and Corporate Presentation

8-Jun-2023	Launch of LUMOS2 Study

7-Jun-2023	Constitution

5-Jun-2023	Appointment of Non-executive Director

26-May-2023	Kazia CEO participates in White House Cancer Moonshot Forum

25-May-2023	Cancel - Notification of cessation of securities - KZA

8-May-2023	Notification regarding unquoted securities - KZA

5-May-2023	Notification of cessation of securities - KZA

2-May-2023	Final Director's Interest Notice - Dr J Garner

1-May-2023	Executive Leadership changes - Dr John Friend appointed CEO

28-Apr-2023	Quarterly Activities/Appendix 4C Cash Flow Report

14-Apr-2023	Kazia regains compliance with Nasdaq minimum bid requirement

12-Apr-2023	Notification of cessation of securities - KZA

6-Apr-2023	Change in substantial holding

4-Apr-2023	Kazia presents new data at AACR Annual Meeting

21-Mar-2023	Change of Director's Interest Notice

17-Mar-2023	Change of Director's Interest Notice

8-Mar-2023	Notification of cessation of securities - KZA

7-Mar-2023	Clinical Collaboration for Phase II clinical study

7-Mar-2023	Change in substantial holding

6-Mar-2023	Change in substantial holding

6-Mar-2023	Change of Director's Interest Notices

6-Mar-2023	Notification regarding unquoted securities - KZA

3-Mar-2023	Cleansing Notice

3-Mar-2023	Application for quotation of securities - KZA

2-Mar-2023	Change in substantial holding

28-Feb-2023	Resignation and appointment of Company Secretary

28-Feb-2023	Half Yearly Report and Accounts

28-Feb-2023	Kazia result of Share Purchase Plan

28-Feb-2023	Cleansing notice

28-Feb-2023	Application for quotation of securities - KZA

24-Feb-2023	Results of EGM

24-Feb-2023	Details of Auditor Appointment/Resignation

15-Feb-2023	Quarterly Activities/Appendix 4C Cash Flow Report

31-Jan-2023	Quarterly Activities/Appendix 4C Cash Flow Report

24-Jan-2023	Substantial shareholder notice

19-Jan-2023	Kazia Share Purchase Plan

19-Jan-2023	Notice of Extraordinary General Meeting/Proxy Form

18-Jan-2023	Change in substantial holding

18-Jan-2023	Change in substantial holding

17-Jan-2023	Cleansing notice

17-Jan-2023	Cleansing notice

17-Jan-2023	Application for quotation of securities - KZA

17-Jan-2023	Application for quotation of securities - KZA

17-Jan-2023	Proposed issue of securities - KZA

16-Jan-2023	Proposed issue of securities - KZA

16-Jan-2023	Kazia raises $4.5m and launches share purchase plan

12-Jan-2023	Trading Halt

15-Dec-2022	Kazia pre-clinical collaboration with QIMR

13-Dec-2022	Kazia receives Nasdaq minimum bid notice

1-Dec-2022	EVT801 preclinical data published

16-Nov-2022	Kazia AGM results

16-Nov-2022	AGM materials

14-Nov-2022	Change in substantial holding

9-Nov-2022	Kazia presents to Bell Potter Healthcare Conference

9-Nov-2022	Kazia to present to SNO

7-Nov-2022	Change in substantial holding

4-Nov-2022	Cleansing notice

4-Nov-2022	Application for quotation of securities - KZA

3-Nov-2022	Withdrawal of resolution

1-Nov-2022	Change in substantial holding

31-Oct-2022	Quarterly Activities/Appendix 4C Cash Flow Report

28-Oct-2022	Change in substantial holding

27-Oct-2022	Positive melanoma data for Kazia's paxalisib

18-Oct-2022	Kazia SEC Form 20F

14-Oct-2022	Notice of Annual General Meeting/Proxy Form

13-Oct-2022	Cleansing notice

13-Oct-2022	Application for quotation of securities - KZA

6-Oct-2022	Expansion of PNOC study into Australia

26-Sep-2022	Kazia AGM date

21-Sep-2022	Cleansing notice

21-Sep-2022	Application for quotation of securities - KZA

16-Sep-2022	Cleansing notice

16-Sep-2022	Application for quotation of securities - KZA

14-Sep-2022	Kazia presentation to HCW Bioconnect

8-Sep-2022	Kazia to present at ESMO

8-Sep-2022	Change in Directors interests

8-Sep-2022	Ceasing to be a substantial holder

29-Aug-2022	Kazia Annual Report to shareholders

29-Aug-2022	Kazia Appendix 4E

29-Aug-2022	Kazia Appendix 4G

29-Aug-2022	Kazia Corporate Governance Statement

23-Aug-2022	Change in substantial holding

16-Aug-2022	Change in substantial holding

15-Aug-2022	Cleansing Notice

15-Aug-2022	Application for quotation of securities - KZA

10-Aug-2022	Change in substantial holding

10-Aug-2022	Change in substantial holding

8-Aug-2022	Notification of cessation of securities - KZA

8-Aug-2022	Interim data from MSKCC study

1-Aug-2022	GBM Agile Update

29-Jul-2022	Quarterly Activities/Appendix 4C Cash Flow Report

29-Jul-2022	Quarterly Activities/Appendix 4C Cash Flow Report

12-Jul-2022	Kazia launches new SAB

8-Jul-2022	Cleansing notice

8-Jul-2022	Application for quotation of securities - KZA

6-Jul-2022	FDA grants RPDD to paxaliaib for AT/RT

30-Jun-2022	Kazia progress update

27-Jun-2022	Ceasing to be a substantial holder

27-Jun-2022	Change in substantial holding

24-Jun-2022	Cleansing notice

24-Jun-2022	Application for quotation of securities - KZA

23-Jun-2022	Kazia presentation on paxalisib for childhood brain cancer

23-Jun-2022	Change in substantial holding

17-Jun-2022	Cleansing Notice

17-Jun-2022	Application for quotation of securities - KZA

17-Jun-2022	FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT

14-Jun-2022	Kazia paxalisib preclinical DIPG data released at IPSNO

10-Jun-2022	Cleansing notice

10-Jun-2022	Application for quotation of securities - KZA

8-Jun-2022	Kazia's Alliance study progresses to expansion phase

6-Jun-2022	Cleansing notice

6-Jun-2022	Proposed issue of securities - KZA

3-Jun-2022	Kazia presents final PII data at ASCO

2-Jun-2022	Application for quotation of securities - KZA

1-Jun-2022	Proposed issue of securities - KZA

31-May-2022	GBM Agile opens to paxalisib in Europe

30-May-2022	Cleansing notice

25-May-2022	Application for quotation of securities - KZA

24-May-2022	Notification regarding unquoted securities - KZA

17-May-2022	Kazia marks DIPG Awareness Day

12-May-2022	Application for quotation of securities - KZA

11-May-2022	Cleansing notice

11-May-2022	Notification regarding unquoted securities - KZA

6-May-2022	Application for quotation of securities - KZA

5-May-2022	Update - Proposed issue of securities - KZA

29-Apr-2022	Kazia to present at ASCO

29-Apr-2022	Quarterly Activities/Appendix 4C Cash Flow Report

28-Apr-2022	Proposed issue of securities - KZA

26-Apr-2022	Kazia establishes ATM program

22-Apr-2022	Proposed issue of securities - KZA

21-Apr-2022	Kazia's paxalisib Phase II trial achieves completion

8-Apr-2022	Kazia presents preclinical data for paxalisib at AACR

8-Apr-2022	Kazia presents on EVT801 at AACR

6-Apr-2022	Kazia response to SEC comments letter

21-Mar-2022	Kazia to present at two conferences

2-Mar-2022	Change in substantial holding

28-Feb-2022	First patient into Cornell keto study

23-Feb-2022	Kazia Half Year Accounts and Appx 4D

1-Feb-2022	Notification regarding unquoted securities - KZA

31-Jan-2022	Quarterly Activities/Appendix 4C Cash Flow Report

19-Jan-2022	Kazia Corporate Deck

22-Dec-2021	Change of Director's Interest Notice

21-Dec-2021	Change of Director's Interest Notice * 3

17-Dec-2021	Change in substantial holding

15-Dec-2021	Issue of shares

13-Dec-2021	Kazia appoints Karen Krumeich as CFO

3-Dec-2021	Kazia releases final data from P2 paxalisib trial

29-Nov-2021	GBM Agile opens to paxalisib in Canada

24-Nov-2021	Notification of cessation of securities - KZA

16-Nov-2021	Notification regarding unquoted securities - KZA

15-Nov-2021	Kazia appoints John Friend as CMO

11-Nov-2021	Kazia enrols first patient to PNOC study

10-Nov-2021	Kazia AGM - Results of Meeting

4-Nov-2021	Notification of cessation of securities - KZA

4-Nov-2021	Notification of cessation of securities - KZA

4-Nov-2021	Kazia enrols first patient to EVT801 Phase I clinical trial

29-Oct-2021	Quarterly Activities/Appendix 4C Cash Flow Report

13-Oct-2021	Notice of General Meeting/Proxy Form

20-Sep-2021	Kazia AGM date

10-Sep-2021	Notification of cessation of securities - KZA

9-Sep-2021	Notification regarding unquoted securities - KZA

2-Sep-2021	Kazia's EVT801 phase I trial receives regulatory approval

2-Sep-2021	Shareholder information - amendment

30-Aug-2021	Change in Directors interests

26-Aug-2021	Kazia Annual Report to shareholders

26-Aug-2021	Kazia Corporate Governance Statement

26-Aug-2021	Kazia Appendix 4G

26-Aug-2021	Kazia Appendix 4E

16-Aug-2021	Kazia corporate presentation

30-Jul-2021	Quarterly Activities/Appendix 4C Cash Flow Report

30-Jun-2021	Kazia update

24-Jun-2021	Manufacturing patents granted for paxalisib

21-Jun-2021	Ceasing to be a substantial holder

15-Jun-2021	Kazia launches new paxalisib phase II clinical trial

7-Jun-2021	Kazia paxalisib in Dana Farber study enrols first patient

2-Jun-2021	Appendix 3Y for 3 directors

27-May-2021	Change in substantial holding

21-May-2021	Appendix 2A

10-May-2021	Change in substantial holding

4-May-2021	Change of directors interests * 3

30-Apr-2021	Cleansing notice

30-Apr-2021	Appendix 4C - quarterly

28-Apr-2021	Appendix 2A

19-Apr-2021	Kazia Corporate Presentation

19-Apr-2021	Kazia licenses EVT801 from Evotec

16-Apr-2021	Trading Halt

9-Apr-2021	Kazia presents PK data for paxalisib at AACR meeting

8-Apr-2021	Change in substantial holding

30-Mar-2021	Change in substantial holding

30-Mar-2021	Proposed issue of Securities - KZA

30-Mar-2021	Proposed issue of Securities - KZA

29-Mar-2021	Kazia licenses paxalisib to Simcere in Greater China

26-Mar-2021	Trading Halt

18-Mar-2021	Kazia March Newsletter

15-Mar-2021	Appendix 2A

15-Mar-2021	Proposed issue of Securities - KZA

2-Mar-2021	Appendix 2A

1-Mar-2021	Kazia licenses Cantrixil to Oasmia

26-Feb-2021	Change in substantial holding

25-Feb-2021	Proposed issue of Securities - KZA

24-Feb-2021	Kazia half year accounts and Appx 4D

11-Feb-2021	Change in substantial holding

29-Jan-2021	Appendix 4C - quarterly

22-Jan-2021	Kazia presents to ShareCafe Hidden Gems webinar

7-Jan-2021	Kazia commences recruitment to GBM AGILE

5-Jan-2021	Kazia presents to HCW BIOCONNECT

4-Jan-2021	Appendix 3G Issue of staff options

17-Dec-2020	Change in directors interest

17-Dec-2020	Change in directors interests

14-Dec-2020	Change in directors interests

14-Dec-2020	Kazia receives $1.02m R&D cash rebate

14-Dec-2020	Kazia presents to LD Micro Main Event

14-Dec-2020	Change in substantial holding

10-Dec-2020	paxalisib PNOC collaboration

9-Dec-2020	Kazia releases Cantrixil top line final data

26-Nov-2020	Kazia presentation to Bell Potter Healthcare Conference

26-Nov-2020	Change in substantial holding

24-Nov-2020	Change in substantial holding

23-Nov-2020	Kazia investor briefing transcript

23-Nov-2020	Change in substantial holding

19-Nov-2020	Change in substantial holding

18-Nov-2020	Kazia's paxalisib SNO data

12-Nov-2020	Kazia presents to HCW Israel conference

10-Nov-2020	Change in directors interests * 4

10-Nov-2020	Kazia issue of options

6-Nov-2020	Kazia Results of Annual General Meeting

6-Nov-2020	Kazia AGM materials

4-Nov-2020	Change in substantial holding

2-Nov-2020	Kazia unmarketable parcel share sale facility

30-Oct-2020	Quarterly Activities Report and Appendix 4C

29-Oct-2020	Change in substantial holding

29-Oct-2020	Becoming a substantial holder

29-Oct-2020	Change in substantial holding

23-Oct-2020	Kazia Appendix 2A retail offer

23-Oct-2020	Change in substantial holding

22-Oct-2020	Kazia Completion of Retail Offer

16-Oct-2020	Kazia executes GBM Agile study agreement

14-Oct-2020	Kazia change in directors interests * 4

14-Oct-2020	Change in substantial holding

13-Oct-2020	Becoming a substantial holder

9-Oct-2020	Kazia Appendix 2A

8-Oct-2020	Kazia letter to ineligible shareholders

8-Oct-2020	Kazia retail entitlement offer booklet

5-Oct-2020	Kazia Notice of AGM and updated proxy form

2-Oct-2020	Kazia Investor Webinar

2-Oct-2020	Update - Proposed issue of Securities - KZA

2-Oct-2020	Kazia successfully completes institutional entitlement offer

1-Oct-2020	Kazia Cleansing Notice

1-Oct-2020	Proposed issue of Securities - KZA

1-Oct-2020	Kazia Investor Presentation

1-Oct-2020	Kazia launch of Entitlement Offer

30-Sep-2020	Trading Halt

28-Sep-2020	Kazia Notice of Annual General Meeting/Proxy Form

28-Sep-2020	Kazia Notice of Extraordinary General Meeting/Proxy Form

22-Sep-2020	Kazia new collaboration with Dana-Farber Cancer Institute

18-Sep-2020	Kazia AGM and closing date for director nominations

15-Sep-2020	Kazia presents to H C Wainwright conference

31-Aug-2020	Conversion of options

31-Aug-2020	Kazia change in directors interests

28-Aug-2020	Kazia change in directors interests

27-Aug-2020	Kazia Appendix 4E

27-Aug-2020	Kazia Annual Report to shareholders

27-Aug-2020	Kazia Corporate Governance Statement

27-Aug-2020	Kazia Appendix 4G

25-Aug-2020	Change in substantial holding

24-Aug-2020	Kazia's paxalisib awarded Orphan Drug Designation

21-Aug-2020	Change in substantial holding

20-Aug-2020	Kazia's paxalisib granted Fast Track Designation by FDA

19-Aug-2020	Change in substantial holding

14-Aug-2020	Change in substantial holding

7-Aug-2020	Kazia's paxalisib obtains Rare Pediatric Disease Designation

31-Jul-2020	Appendix 4C - quarterly

27-Jul-2020	Change in substantial holding

20-Jul-2020	Ceasing to be a substantial holder

25-Jun-2020	Kazia presents to Hidden Gems ShareCafe Investor Webinar

19-Jun-2020	Change in substantial holding

16-Jun-2020	Kazia presentation to TKIRW

3-Jun-2020	Expiry of options

27-May-2020	Appendix 3Y Iain Ross

26-May-2020	Appendix 2A conversion of options

11-May-2020	Change of Director's Interest Notice x4

8-May-2020	Kazia Appendix 2A

8-May-2020	Change in substantial holding

6-May-2020	Kazia Share Purchase Plan raises $1.8m

1-May-2020	Kazia Share Purchase Plan extended

29-Apr-2020	Kazia Share Purchase Plan reminder

22-Apr-2020	Becoming a substantial holder

21-Apr-2020	Change in substantial holding

21-Apr-2020	Change in substantial holding

17-Apr-2020	Kazia cleansing statement

17-Apr-2020	Kazia share purchase plan

17-Apr-2020	Cantrixil last patient visit

16-Apr-2020	Kazia Appendix 2A

15-Apr-2020	Kazia transcript of investor call

9-Apr-2020	Change in substantial holding

8-Apr-2020	Proposed issue of Securities - KZA

8-Apr-2020	Proposed issue of Securities - KZA

8-Apr-2020	Kazia placement and Share Purchase Plan

7-Apr-2020	Trading Halt

7-Apr-2020	Kazia paxalisib Phase II interim data

7-Apr-2020	Change in substantial holding

19-Mar-2020	Change in substantial holding

17-Mar-2020	Kazia March 2020 newsletter

6-Mar-2020	Completion of recruitment to paxalisib P2 GBM study

6-Mar-2020	Change in substantial holding

24-Feb-2020	Kazia change in directors interests SC and JG

20-Feb-2020	Kazia Half Year Accounts and Chairman's letter

13-Jan-2020	Appendix 3B and Appendix 3G - ESOP

13-Jan-2020	Kazia presents at Biotech Showcase

24-Dec-2019	Kazia receives $1.4m R&D cash rebate

20-Dec-2019	Kazia EGM results

20-Dec-2019	Change in substantial holding

16-Dec-2019	ASX waiver on voting restrictions

12-Dec-2019	Change in substantial holding

11-Dec-2019	Kazia joins GBM Agile

5-Dec-2019	Change in substantial holding

3-Dec-2019	Change of directors interest notice - James Garner

3-Dec-2019	Change of directors interest notice - Iain Ross

3-Dec-2019	Kazia presents to Switzer Investment Conference

27-Nov-2019	Kazia GDC-0084 investor call transcript

26-Nov-2019	Appendix 3Y

26-Nov-2019	Appendix 3Y

25-Nov-2019	Ceasing to be a substantial holder

21-Nov-2019	Trading Halt

20-Nov-2019	Kazia Appendix 4G and Corporate Governance Statement

14-Nov-2019	Kazia AGM webcast

13-Nov-2019	Appendix 3B and Appendix 3Y

13-Nov-2019	Results of Meeting

13-Nov-2019	Kazia AGM presentations

11-Nov-2019	Kazia notice of meeting for EGM

6-Nov-2019	Becoming a substantial holder

5-Nov-2019	Change in substantial holding

5-Nov-2019	Change in substantial holding

1-Nov-2019	Appendix 3B cleansing statement and disclosures

31-Oct-2019	Kazia presents to AusBiotech Invest

28-Oct-2019	Kazia raises $4 million

24-Oct-2019	Trading Halt

14-Oct-2019	Kazia Notice of Annual General Meeting/Proxy Form

26-Sep-2019	Kazia September newsletter

12-Sep-2019	MTD achieved in St Jude study in DIPG

4-Sep-2019	Change in Directors interests - James Garner

29-Aug-2019	Kazia Annual Report to shareholders

29-Aug-2019	Kazia Appendix 4E

23-Aug-2019	WHO selects provisional name for Kazia's GDC-0084

13-Aug-2019	Kazia completes recruitment to Cantrixil Phase 1 trial

22-Jul-2019	Kazia collaboration with MSK

10-Jul-2019	Substantial shareholder change in interests

3-Jul-2019	Appendix 3Y for 4 directors

3-Jul-2019	Change in substantial shareholder interest

25-Jun-2019	Kazia presents to Gold Coast Investment Showcase

24-Jun-2019	Kazia June Newsletter

20-May-2019	Kazia's GDC-0084 joins Alliance trial in brain cancer

9-May-2019	BNYM substantial shareholder notice

8-May-2019	Becoming a substantial holder

6-May-2019	Top-line safety data from Kazia's GDC-0084 phase II study

5-Apr-2019	Appendix 3Y James Garner

3-Apr-2019	Amended Appendix 3Y Iain Ross

3-Apr-2019	Appendix 3Y Iain Ross

1-Apr-2019	Kazia presents Cantrixil Phase I data at AACR

19-Mar-2019	Kazia sells stake in Noxopharm

18-Mar-2019	Appendix 3B placement capacity

20-Feb-2019	Kazia half-year report and Chairman's letter

18-Feb-2019	Kazia presentation to Proactive Investors

15-Jan-2019	Kazia receives $2.2m R&D cash rebate

7-Jan-2019	Kazia presentation to Biotech Showcase

7-Jan-2019	Appendix 3B amended

4-Jan-2019	Appendix 3B

7-Dec-2018	Appendix 3Y James Garner

3-Dec-2018	Kazia Appendix 3Y

26-Nov-2018	Change in directors' interests * 4

23-Nov-2018	Appendix 3B and cleansing notice

20-Nov-2018	Kazia SPP raises $0.8 million

13-Nov-2018	Appendiz 3Y Iain Ross

12-Nov-2018	Appendix 3B amendment

12-Nov-2018	Kazia AGM recording

9-Nov-2018	Appendix 3B & Cleansing Notice

8-Nov-2018	AGM results

8-Nov-2018	AGM presentations

5-Nov-2018	Kazia November Newsletter

30-Oct-2018	Kazia presents to AusBiotech Invest

29-Oct-2018	GDC-0084 update

26-Oct-2018	Becoming a substantial holder

24-Oct-2018	Section 708 notice

24-Oct-2018	Appendix 3B and Listing Rules disclosures

23-Oct-2018	Kazia Share Purchase Plan

22-Oct-2018	Kazia breast mets collaboration with Dana-Farber

18-Oct-2018	Reinstatement to Official Quotation

18-Oct-2018	Kazia raises $3.4m to progress R&D programs

17-Oct-2018	Suspension from Official Quotation

15-Oct-2018	Trading Halt

11-Oct-2018	Presentation to Finance News Network Investor Event

10-Oct-2018	Cantrixil Part A completion

8-Oct-2018	Kazia Notice of Meeting

8-Oct-2018	Kazia Annual Report to shareholders, Appx 4G, Corporate Governance Statement

3-Oct-2018	Kazia change in interest of substantial shareholder

3-Oct-2018	Kazia collaborates with St Jude Children's Research Hospital

14-Sep-2018	Kazia attains Milestone 1 under Glioblast Purchase Agreement

29-Aug-2018	Kazia Appendix 4E and financial report

20-Jul-2018	Kazia files shelf registration statement with SEC

16-Jul-2018	Kazia Shareholder Presentation

13-Jul-2018	Kazia divests ATM program

10-Jul-2018	Kazia shareholder information sessions UPDATE

3-Jul-2018	Kazia change in interests of substantial shareholder

25-Jun-2018	Kazia Shareholder Information Sessions

21-Jun-2018	Kazia presents at Gold Coast Investment Showcase

19-Jun-2018	Kazia releases preliminary Cantrixil Phase I data

21-May-2018	Progress Report

11-May-2018	Kazia Shareholder Newsletter

29-Mar-2018	Kazia commences Phase II clinical study of GDC-0084

19-Mar-2018	Kazia presentation to Proactive Investors CEO series

7-Mar-2018	Notice of change in interests of substantial holder

6-Mar-2018	Kazia responds to share trading on ASX and Nasdaq

23-Feb-2018	Kazia receives FDA orphan drug designation for GDC 0084

21-Feb-2018	Kazia Appendix 4D, Half yearly accounts and Chairmans letter

19-Feb-2018	Kazia change of address

19-Feb-2018	Kazia receives $4m R&D tax rebate

5-Feb-2018	Kazia Appendix 3B

30-Jan-2018	Notice of change of interests of substantial holder

22-Jan-2018	Receipt of securities in Noxopharm Limited (NOX)

15-Jan-2018	Kazia change of interests of substantial shareholder

10-Jan-2018	Kazia presentation to Biotech Showcase